ID   AKT2_HUMAN              Reviewed;         481 AA.
AC   P31751; B2RBD8; Q05BV0; Q0VAN0; Q0VAN1; Q68GC0;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   22-JUL-2015, entry version 170.
DE   RecName: Full=RAC-beta serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Akt-2;
DE   AltName: Full=Protein kinase B beta;
DE            Short=PKB beta;
DE   AltName: Full=RAC-PK-beta;
GN   Name=AKT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Epithelium;
RX   PubMed=1801921;
RA   Jones P.F., Jakubowicz T., Hemmings B.A.;
RT   "Molecular cloning of a second form of rac protein kinase.";
RL   Cell Regul. 2:1001-1009(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1409633; DOI=10.1073/pnas.89.19.9267;
RA   Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F.,
RA   Hamilton T.C., Tsichlis P.N., Testa J.R.;
RT   "AKT2, a putative oncogene encoding a member of a subfamily of
RT   protein-serine/threonine kinases, is amplified in human ovarian
RT   carcinomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9267-9271(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 237-277.
RG   NIEHS SNPs program;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   CHARACTERIZATION, AND PHOSPHORYLATION AT THR-309 BY PDPK1.
RX   PubMed=9512493;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in
RT   vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro:
RT   comparison with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [8]
RP   INTERACTION WITH MTCP1; TCL1A AND TCL1B.
RX   PubMed=10983986; DOI=10.1016/S1097-2765(00)00039-3;
RA   Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.;
RT   "The protooncogene TCL1 is an Akt kinase coactivator.";
RL   Mol. Cell 6:395-407(2000).
RN   [9]
RP   MUTAGENESIS OF THR-309 AND SER-474, AND PHOSPHORYLATION AT THR-309 AND
RP   SER-474.
RX   PubMed=15890450; DOI=10.1016/j.bbagen.2005.04.002;
RA   Baer K., Lisinski I., Gompert M., Stuhlmann D., Schmolz K.,
RA   Klein H.W., Al-Hasani H.;
RT   "Activation of a GST-tagged AKT2/PKBbeta.";
RL   Biochim. Biophys. Acta 1725:340-347(2005).
RN   [10]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16540465; DOI=10.1074/jbc.M601384200;
RA   Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A.,
RA   Kendall R.L.;
RT   "Kinetic mechanism of AKT/PKB enzyme family.";
RL   J. Biol. Chem. 281:13949-13956(2006).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PBH2.
RX   PubMed=17565718; DOI=10.1002/jcp.21177;
RA   Heron-Milhavet L., Mamaeva D., Rochat A., Lamb N.J., Fernandez A.;
RT   "Akt2 is implicated in skeletal muscle differentiation and
RT   specifically binds Prohibitin2/REA.";
RL   J. Cell. Physiol. 214:158-165(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   UBIQUITINATION BY TTC3, PHOSPHORYLATION AT THR-309 AND SER-474, AND
RP   MUTAGENESIS OF THR-309 AND SER-474.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J.,
RA   Hirata N., Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C.,
RA   Hatakeyama S., Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [14]
RP   INTERACTION WITH CLIP3, AND SUBCELLULAR LOCATION.
RX   PubMed=19139280; DOI=10.1128/MCB.00754-08;
RA   Ding J., Du K.;
RT   "ClipR-59 interacts with Akt and regulates Akt cellular
RT   compartmentalization.";
RL   Mol. Cell. Biol. 29:1459-1471(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447; THR-451; SER-474
RP   AND SER-478, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   UBIQUITINATION, AND INTERACTION WITH TRAF6.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [17]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=20167810; DOI=10.1093/neuonc/nop026;
RA   Mure H., Matsuzaki K., Kitazato K.T., Mizobuchi Y., Kuwayama K.,
RA   Kageji T., Nagahiro S.;
RT   "Akt2 and Akt3 play a pivotal role in malignant gliomas.";
RL   Neuro-oncol. 12:221-232(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
RA   Hers I., Vincent E.E., Tavare J.M.;
RT   "Akt signalling in health and disease.";
RL   Cell. Signal. 23:1515-1527(2011).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=21432781;
RA   Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.;
RT   "Akt1 and Akt2: differentiating the aktion.";
RL   Histol. Histopathol. 26:651-662(2011).
RN   [21]
RP   FUNCTION IN MUSCLE DIFFERENTIATION, AND INTERACTION WITH ANKRD2.
RX   PubMed=21737686; DOI=10.1091/mbc.E10-11-0928;
RA   Cenni V., Bavelloni A., Beretti F., Tagliavini F., Manzoli L.,
RA   Lattanzi G., Maraldi N.M., Cocco L., Marmiroli S.;
RT   "Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic
RT   differentiation upon cellular exposure to H(2)O(2).";
RL   Mol. Biol. Cell 22:2946-2956(2011).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34 AND THR-451, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480.
RX   PubMed=12086620; DOI=10.1016/S1097-2765(02)00550-6;
RA   Yang J., Cron P., Thompson V., Good V.M., Hess D., Hemmings B.A.,
RA   Barford D.;
RT   "Molecular mechanism for the regulation of protein kinase B/Akt by
RT   hydrophobic motif phosphorylation.";
RL   Mol. Cell 9:1227-1240(2002).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 146-467 IN COMPLEX WITH
RP   PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER AND MANGANESE, AND
RP   PHOSPHORYLATION AT THR-309.
RX   PubMed=12434148; DOI=10.1038/nsb870;
RA   Yang J., Cron P., Good V.M., Thompson V., Hemmings B.A., Barford D.;
RT   "Crystal structure of an activated Akt/protein kinase B ternary
RT   complex with GSK3-peptide and AMP-PNP.";
RL   Nat. Struct. Biol. 9:940-944(2002).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 143-481, ATP-BINDING,
RP   SUBSTRATE-BINDING, AND DISULFIDE BOND.
RX   PubMed=12517337; DOI=10.1016/S0969-2126(02)00937-1;
RA   Huang X., Begley M., Morgenstern K.A., Gu Y., Rose P., Zhao H.,
RA   Zhu X.;
RT   "Crystal structure of an inactive Akt2 kinase domain.";
RL   Structure 11:21-30(2003).
RN   [27]
RP   STRUCTURE BY NMR OF 1-111.
RX   PubMed=14755158; DOI=10.1023/B:JNMR.0000013836.62154.c2;
RA   Auguin D., Barthe P., Auge-Senegas M.T., Stern M.H., Noguchi M.,
RA   Roumestand C.;
RT   "Solution structure and backbone dynamics of the pleckstrin homology
RT   domain of the human protein kinase B (PKB/Akt). Interaction with
RT   inositol phosphates.";
RL   J. Biomol. NMR 28:137-155(2004).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 146-467, AND
RP   INHIBITOR-BINDING.
RX   PubMed=17275837; DOI=10.1016/j.jmb.2007.01.004;
RA   Davies T.G., Verdonk M.L., Graham B., Saalau-Bethell S., Hamlett C.C.,
RA   McHardy T., Collins I., Garrett M.D., Workman P., Woodhead S.J.,
RA   Jhoti H., Barford D.;
RT   "A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB
RT   chimera.";
RL   J. Mol. Biol. 367:882-894(2007).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 146-480, AND ENZYME
RP   REGULATION.
RX   PubMed=18800763; DOI=10.1021/jm8004527;
RA   Heerding D.A., Rhodes N., Leber J.D., Clark T.J., Keenan R.M.,
RA   Lafrance L.V., Li M., Safonov I.G., Takata D.T., Venslavsky J.W.,
RA   Yamashita D.S., Choudhry A.E., Copeland R.A., Lai Z., Schaber M.D.,
RA   Tummino P.J., Strum S.L., Wood E.R., Duckett D.R., Eberwein D.,
RA   Knick V.B., Lansing T.J., McConnell R.T., Zhang S., Minthorn E.A.,
RA   Concha N.O., Warren G.L., Kumar R.;
RT   "Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-
RT   7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-
RT   methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.";
RL   J. Med. Chem. 51:5663-5679(2008).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480, AND ENZYME
RP   REGULATION.
RX   PubMed=19179070; DOI=10.1016/j.bmcl.2009.01.002;
RA   Rouse M.B., Seefeld M.A., Leber J.D., McNulty K.C., Sun L.,
RA   Miller W.H., Zhang S., Minthorn E.A., Concha N.O., Choudhry A.E.,
RA   Schaber M.D., Heerding D.A.;
RT   "Aminofurazans as potent inhibitors of AKT kinase.";
RL   Bioorg. Med. Chem. Lett. 19:1508-1511(2009).
RN   [31]
RP   VARIANT NIDDM HIS-274.
RX   PubMed=15166380; DOI=10.1126/science.1096706;
RA   George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S.,
RA   Wilson J.C., Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L.,
RA   Dunger D.B., Barford D., Umpleby A.M., Wareham N.J., Davies H.A.,
RA   Schafer A.J., Stoffel M., O'Rahilly S., Barroso I.;
RT   "A family with severe insulin resistance and diabetes due to a
RT   mutation in AKT2.";
RL   Science 304:1325-1328(2004).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-188 AND LYS-208.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [33]
RP   ASSOCIATION OF VARIANT NIDDM HIS-274 WITH TYPICAL METABOLIC
RP   DYSLIPIDEMIA.
RX   PubMed=19164855; DOI=10.1172/JCI37432;
RA   Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L.,
RA   Jackson S., Vottero A., Kanabar D., Charlton-Menys V., Durrington P.,
RA   Soos M.A., Carpenter T.A., Lomas D.J., Cochran E.K., Gorden P.,
RA   O'Rahilly S., Savage D.B.;
RT   "Postreceptor insulin resistance contributes to human dyslipidemia and
RT   hepatic steatosis.";
RL   J. Clin. Invest. 119:315-322(2009).
RN   [34]
RP   VARIANT HIHGHH LYS-17.
RX   PubMed=21979934; DOI=10.1126/science.1210878;
RA   Hussain K., Challis B., Rocha N., Payne F., Minic M., Thompson A.,
RA   Daly A., Scott C., Harris J., Smillie B.J., Savage D.B., Ramaswami U.,
RA   De Lonlay P., O'Rahilly S., Barroso I., Semple R.K.;
RT   "An activating mutation of AKT2 and human hypoglycemia.";
RL   Science 334:474-474(2011).
CC   -!- FUNCTION: AKT2 is one of 3 closely related serine/threonine-
CC       protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and
CC       which regulate many processes including metabolism, proliferation,
CC       cell survival, growth and angiogenesis. This is mediated through
CC       serine and/or threonine phosphorylation of a range of downstream
CC       substrates. Over 100 substrate candidates have been reported so
CC       far, but for most of them, no isoform specificity has been
CC       reported. AKT is responsible of the regulation of glucose uptake
CC       by mediating insulin-induced translocation of the SLC2A4/GLUT4
CC       glucose transporter to the cell surface. Phosphorylation of PTPN1
CC       at 'Ser-50' negatively modulates its phosphatase activity
CC       preventing dephosphorylation of the insulin receptor and the
CC       attenuation of insulin signaling. Phosphorylation of TBC1D4
CC       triggers the binding of this effector to inhibitory 14-3-3
CC       proteins, which is required for insulin-stimulated glucose
CC       transport. AKT regulates also the storage of glucose in the form
CC       of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at
CC       'Ser-9', resulting in inhibition of its kinase activity.
CC       Phosphorylation of GSK3 isoforms by AKT is also thought to be one
CC       mechanism by which cell proliferation is driven. AKT regulates
CC       also cell survival via the phosphorylation of MAP3K5 (apoptosis
CC       signal-related kinase). Phosphorylation of 'Ser-83' decreases
CC       MAP3K5 kinase activity stimulated by oxidative stress and thereby
CC       prevents apoptosis. AKT mediates insulin-stimulated protein
CC       synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462',
CC       thereby activating mTORC1 signaling and leading to both
CC       phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is
CC       involved in the phosphorylation of members of the FOXO factors
CC       (Forkhead family of transcription factors), leading to binding of
CC       14-3-3 proteins and cytoplasmic localization. In particular, FOXO1
CC       is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and
CC       FOXO4 are phosphorylated on equivalent sites. AKT has an important
CC       role in the regulation of NF-kappa-B-dependent gene transcription
CC       and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-
CC       response element binding protein). The phosphorylation of CREB1
CC       induces the binding of accessory proteins that are necessary for
CC       the transcription of pro-survival genes such as BCL2 and MCL1. AKT
CC       phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby
CC       potentially regulating ACLY activity and fatty acid synthesis.
CC       Activates the 3B isoform of cyclic nucleotide phosphodiesterase
CC       (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced
CC       cyclic AMP levels and inhibition of lipolysis. Phosphorylates
CC       PIKFYVE on 'Ser-318', which results in increased PI(3)P-5
CC       activity. The Rho GTPase-activating protein DLC1 is another
CC       substrate and its phosphorylation is implicated in the regulation
CC       cell proliferation and cell growth. AKT plays a role as key
CC       modulator of the AKT-mTOR signaling pathway controlling the tempo
CC       of the process of newborn neurons integration during adult
CC       neurogenesis, including correct neuron positioning, dendritic
CC       development and synapse formation. Signals downstream of
CC       phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of
CC       various growth factors such as platelet-derived growth factor
CC       (PDGF), epidermal growth factor (EGF), insulin and insulin-like
CC       growth factor I (IGF-I). AKT mediates the antiapoptotic effects of
CC       IGF-I. Essential for the SPATA13-mediated regulation of cell
CC       migration and adhesion assembly and disassembly. May be involved
CC       in the regulation of the placental development.
CC   -!- FUNCTION: One of the few specific substrates of AKT2 identified
CC       recently is PITX2. Phosphorylation of PITX2 impairs its
CC       association with the CCND1 mRNA-stabilizing complex thus
CC       shortening the half-life of CCND1. AKT2 seems also to be the
CC       principal isoform responsible of the regulation of glucose uptake.
CC       Phosphorylates C2CD5 on 'Ser-197' during insulin-stimulated
CC       adipocytes. AKT2 is also specifically involved in skeletal muscle
CC       differentiation, one of its substrates in this process being
CC       ANKRD2. Down-regulation by RNA interference reduces the expression
CC       of the phosphorylated form of BAD, resulting in the induction of
CC       caspase-dependent apoptosis. Phosphorylates CLK2 on 'Thr-343'.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Two specific sites, one in the kinase domain
CC       (Thr-309) and the other in the C-terminal regulatory region (Ser-
CC       474), need to be phosphorylated for its full activation.
CC       Aminofurazans are potent AKT2 inhibitors.
CC       {ECO:0000269|PubMed:18800763, ECO:0000269|PubMed:19179070}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=358.4 uM for ATP (for purified and in vitro activated AKT2)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=3.4 uM for peptide substrate (for purified and in vitro
CC         activated AKT2) {ECO:0000269|PubMed:16540465};
CC         KM=564 uM for ATP (for recombinant myristoylated AKT2 expressed
CC         and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=2.3 uM for peptide substrate (for recombinant myristoylated
CC         AKT2 expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC   -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with
CC       KCTD20 (By similarity). Interacts (via PH domain) with MTCP1,
CC       TCL1A AND TCL1B. Interacts with CLK2, PBH2 and TRAF6. Interacts
CC       (when phosphorylated) with CLIP3, the interaction promotes cell
CC       membrane localization (PubMed:19139280).
CC       {ECO:0000250|UniProtKB:Q60823, ECO:0000269|PubMed:10983986,
CC       ECO:0000269|PubMed:12434148, ECO:0000269|PubMed:17565718,
CC       ECO:0000269|PubMed:19139280, ECO:0000269|PubMed:19713527,
CC       ECO:0000269|PubMed:21737686}.
CC   -!- INTERACTION:
CC       P49841:GSK3B; NbExp=2; IntAct=EBI-296058, EBI-373586;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-296058, EBI-352572;
CC       P08670:VIM; NbExp=6; IntAct=EBI-296058, EBI-353844;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane;
CC       Peripheral membrane protein. Note=Localizes within both nucleus
CC       and cytoplasm of proliferative primary myoblasts and mostly within
CC       the nucleus of differentiated primary myoblasts. By virtue of the
CC       N-terminal PH domain, is recruited to sites of the plasma membrane
CC       containing increased PI(3,4,5)P3 or PI(3,4)P2, cell membrane
CC       targeting is also facilitared by interaction with CLIP3.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P31751-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P31751-2; Sequence=VSP_056930;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in all cell types so far analyzed.
CC   -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-
CC       trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-
CC       kinase alpha (PIK3CA) activity results in its targeting to the
CC       plasma membrane.
CC   -!- PTM: Phosphorylation on Thr-309 and Ser-474 is required for full
CC       activity. {ECO:0000269|PubMed:12434148,
CC       ECO:0000269|PubMed:15890450, ECO:0000269|PubMed:20059950,
CC       ECO:0000269|PubMed:9512493}.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT2
CC       ubiquitination. When fully phosphorylated and translocated into
CC       the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by
CC       TTC3, leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:19713527, ECO:0000269|PubMed:20059950}.
CC   -!- PTM: O-GlcNAcylation at Thr-306 and Thr-313 inhibits activating
CC       phosphorylation at Thr-309 via disrupting the interaction between
CC       AKT and PDK1. {ECO:0000250}.
CC   -!- DISEASE: Note=Defects in AKT2 are a cause of susceptibility to
CC       breast cancer (BC). AKT2 promotes metastasis of tumor cells
CC       without affecting the latency of tumor development. With AKT3,
CC       plays also a pivotal role in the biology of glioblastoma.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM)
CC       [MIM:125853]: A multifactorial disorder of glucose homeostasis
CC       caused by a lack of sensitivity to the body's own insulin.
CC       Affected individuals usually have an obese body habitus and
CC       manifestations of a metabolic syndrome characterized by diabetes,
CC       insulin resistance, hypertension and hypertriglyceridemia. The
CC       disease results in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:15166380,
CC       ECO:0000269|PubMed:19164855}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hypoinsulinemic hypoglycemia with hemihypertrophy
CC       (HIHGHH) [MIM:240900]: A disorder characterized by hypoglycemia,
CC       low insulin levels, low serum levels of ketone bodies and
CC       branched-chain amino acids, left-sided hemihypertrophy, neonatal
CC       macrosomia, reduced consciousness and hypoglycemic seizures.
CC       {ECO:0000269|PubMed:21979934}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PH domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00145}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- CAUTION: In light of strong homologies in the primary amino acid
CC       sequence, the 3 AKT kinases were long surmised to play redundant
CC       and overlapping roles. More recent studies has brought into
CC       question the redundancy within AKT kinase isoforms and instead
CC       pointed to isoform specific functions in different cellular events
CC       and diseases. AKT1 is more specifically involved in cellular
CC       survival pathways, by inhibiting apoptotic processes; whereas AKT2
CC       is more specific for the insulin receptor signaling pathway.
CC       Moreover, while AKT1 and AKT2 are often implicated in many aspects
CC       of cellular transformation, the 2 isoforms act in a complementary
CC       opposing manner. The role of AKT3 is less clear, though it appears
CC       to be predominantly expressed in brain. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AKT2ID517ch19q13.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/akt2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77198; AAA36585.1; -; mRNA.
DR   EMBL; M95936; AAA58364.1; -; mRNA.
DR   EMBL; AK314619; BAG37185.1; -; mRNA.
DR   EMBL; AC118344; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032709; AAH32709.1; -; mRNA.
DR   EMBL; BC120995; AAI20996.1; -; mRNA.
DR   EMBL; BC120994; AAI20995.1; -; mRNA.
DR   EMBL; AY708392; AAT97984.1; -; Genomic_DNA.
DR   CCDS; CCDS12552.1; -. [P31751-1]
DR   PIR; A46288; A46288.
DR   RefSeq; NP_001617.1; NM_001626.5. [P31751-1]
DR   RefSeq; XP_011524916.1; XM_011526614.1. [P31751-1]
DR   RefSeq; XP_011524917.1; XM_011526615.1. [P31751-1]
DR   RefSeq; XP_011524918.1; XM_011526616.1. [P31751-1]
DR   RefSeq; XP_011524919.1; XM_011526617.1. [P31751-1]
DR   RefSeq; XP_011524920.1; XM_011526618.1. [P31751-1]
DR   RefSeq; XP_011524921.1; XM_011526619.1. [P31751-1]
DR   RefSeq; XP_011524922.1; XM_011526620.1. [P31751-1]
DR   RefSeq; XP_011524923.1; XM_011526621.1. [P31751-1]
DR   UniGene; Hs.631535; -.
DR   PDB; 1GZK; X-ray; 2.30 A; A=146-460.
DR   PDB; 1GZN; X-ray; 2.50 A; A=146-480.
DR   PDB; 1GZO; X-ray; 2.75 A; A=146-460.
DR   PDB; 1MRV; X-ray; 2.80 A; A=143-481.
DR   PDB; 1MRY; X-ray; 2.80 A; A=143-481.
DR   PDB; 1O6K; X-ray; 1.70 A; A=146-481.
DR   PDB; 1O6L; X-ray; 1.60 A; A=146-467.
DR   PDB; 1P6S; NMR; -; A=1-111.
DR   PDB; 2JDO; X-ray; 1.80 A; A=146-467.
DR   PDB; 2JDR; X-ray; 2.30 A; A=146-467.
DR   PDB; 2UW9; X-ray; 2.10 A; A=146-467.
DR   PDB; 2X39; X-ray; 1.93 A; A=146-467.
DR   PDB; 2XH5; X-ray; 2.72 A; A=146-479.
DR   PDB; 3D0E; X-ray; 2.00 A; A/B=146-480.
DR   PDB; 3E87; X-ray; 2.30 A; A/B=146-480.
DR   PDB; 3E88; X-ray; 2.50 A; A/B=146-480.
DR   PDB; 3E8D; X-ray; 2.70 A; A/B=146-480.
DR   PDBsum; 1GZK; -.
DR   PDBsum; 1GZN; -.
DR   PDBsum; 1GZO; -.
DR   PDBsum; 1MRV; -.
DR   PDBsum; 1MRY; -.
DR   PDBsum; 1O6K; -.
DR   PDBsum; 1O6L; -.
DR   PDBsum; 1P6S; -.
DR   PDBsum; 2JDO; -.
DR   PDBsum; 2JDR; -.
DR   PDBsum; 2UW9; -.
DR   PDBsum; 2X39; -.
DR   PDBsum; 2XH5; -.
DR   PDBsum; 3D0E; -.
DR   PDBsum; 3E87; -.
DR   PDBsum; 3E88; -.
DR   PDBsum; 3E8D; -.
DR   DisProt; DP00304; -.
DR   ProteinModelPortal; P31751; -.
DR   SMR; P31751; 1-480.
DR   BioGrid; 106711; 44.
DR   DIP; DIP-32583N; -.
DR   IntAct; P31751; 22.
DR   MINT; MINT-87790; -.
DR   STRING; 9606.ENSP00000375892; -.
DR   BindingDB; P31751; -.
DR   ChEMBL; CHEMBL2111353; -.
DR   GuidetoPHARMACOLOGY; 1480; -.
DR   PhosphoSite; P31751; -.
DR   BioMuta; AKT2; -.
DR   DMDM; 1170703; -.
DR   MaxQB; P31751; -.
DR   PaxDb; P31751; -.
DR   PRIDE; P31751; -.
DR   DNASU; 208; -.
DR   Ensembl; ENST00000311278; ENSP00000309428; ENSG00000105221. [P31751-2]
DR   Ensembl; ENST00000392038; ENSP00000375892; ENSG00000105221.
DR   Ensembl; ENST00000424901; ENSP00000399532; ENSG00000105221. [P31751-2]
DR   GeneID; 208; -.
DR   UCSC; uc002one.3; human. [P31751-1]
DR   UCSC; uc010egs.3; human.
DR   CTD; 208; -.
DR   GeneCards; GC19M040736; -.
DR   HGNC; HGNC:392; AKT2.
DR   HPA; CAB004204; -.
DR   MIM; 125853; phenotype.
DR   MIM; 164731; gene.
DR   MIM; 240900; phenotype.
DR   neXtProt; NX_P31751; -.
DR   Orphanet; 79085; Familial partial lipodystrophy due to AKT2 mutations.
DR   Orphanet; 293964; Hypoinsulinemic hypoglycemia and body hemihypertrophy.
DR   PharmGKB; PA24685; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00770000120449; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P31751; -.
DR   OrthoDB; EOG7Q5HCW; -.
DR   PhylomeDB; P31751; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_115662; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; REACT_12442; AKT phosphorylates targets in the nucleus.
DR   Reactome; REACT_12447; Negative regulation of the PI3K/AKT network.
DR   Reactome; REACT_12564; AKT phosphorylates targets in the cytosol.
DR   Reactome; REACT_13655; AKT-mediated inactivation of FOXO1A.
DR   Reactome; REACT_1451; PDE3B signalling.
DR   Reactome; REACT_147867; Translocation of GLUT4 to the plasma membrane.
DR   Reactome; REACT_1695; GPVI-mediated activation cascade.
DR   Reactome; REACT_19290; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; REACT_19358; CD28 dependent PI3K/Akt signaling.
DR   Reactome; REACT_19405; CTLA4 inhibitory signaling.
DR   Reactome; REACT_263991; VEGFR2 mediated vascular permeability.
DR   Reactome; REACT_264178; deactivation of the beta-catenin transactivating complex.
DR   Reactome; REACT_355377; TP53 Regulates Metabolic Genes.
DR   Reactome; REACT_355468; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; REACT_549; Activation of BAD and translocation to mitochondria.
DR   Reactome; REACT_6743; Inhibition of TSC complex formation by PKB.
DR   Reactome; REACT_75829; PIP3 activates AKT signaling.
DR   Reactome; REACT_790; Activation of PKB.
DR   SignaLink; P31751; -.
DR   ChiTaRS; AKT2; human.
DR   EvolutionaryTrace; P31751; -.
DR   GeneWiki; AKT2; -.
DR   GenomeRNAi; 208; -.
DR   NextBio; 836; -.
DR   PRO; PR:P31751; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; P31751; -.
DR   CleanEx; HS_AKT2; -.
DR   ExpressionAtlas; P31751; baseline and differential.
DR   Genevisible; P31751; HS.
DR   GO; GO:0005938; C:cell cortex; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032593; C:insulin-responsive compartment; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0090630; P:activation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0008643; P:carbohydrate transport; IEA:UniProtKB-KW.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; TAS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0065002; P:intracellular protein transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0010748; P:negative regulation of plasma membrane long-chain fatty acid transport; IMP:BHF-UCL.
DR   GO; GO:0033119; P:negative regulation of RNA splicing; IEA:Ensembl.
DR   GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:2000147; P:positive regulation of cell motility; IMP:BHF-UCL.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:BHF-UCL.
DR   GO; GO:2001275; P:positive regulation of glucose import in response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; ISS:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0031340; P:positive regulation of vesicle fusion; ISS:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IEA:Ensembl.
DR   GO; GO:0071156; P:regulation of cell cycle arrest; TAS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; TAS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0014850; P:response to muscle activity; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0006970; P:response to osmotic stress; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH-like_dom.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Carbohydrate metabolism; Cell membrane;
KW   Complete proteome; Cytoplasm; Developmental protein;
KW   Diabetes mellitus; Disease mutation; Disulfide bond;
KW   Glucose metabolism; Glycogen biosynthesis; Glycogen metabolism;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Sugar transport; Transferase;
KW   Translation regulation; Transport; Ubl conjugation.
FT   CHAIN         1    481       RAC-beta serine/threonine-protein kinase.
FT                                /FTId=PRO_0000085608.
FT   DOMAIN        5    108       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      152    409       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      410    481       AGC-kinase C-terminal.
FT   NP_BIND     158    166       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      230    232       Inhibitor binding.
FT   REGION      277    279       Inhibitor binding.
FT   REGION      292    293       Inhibitor binding.
FT   ACT_SITE    275    275       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     181    181       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     181    181       Inhibitor.
FT   BINDING     200    200       Inhibitor.
FT   BINDING     232    232       Inhibitor; via amide nitrogen.
FT   BINDING     236    236       Inhibitor.
FT   BINDING     279    279       Inhibitor; via carbonyl oxygen.
FT   BINDING     280    280       Manganese. {ECO:0000269|PubMed:12434148}.
FT   BINDING     293    293       Inhibitor.
FT   BINDING     293    293       Manganese. {ECO:0000269|PubMed:12434148}.
FT   BINDING     294    294       Inhibitor; via amide nitrogen.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:22223895}.
FT   MOD_RES      14     14       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES      20     20       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES      34     34       Phosphoserine.
FT                                {ECO:0000269|PubMed:24275569}.
FT   MOD_RES     126    126       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     128    128       Phosphoserine; alternate.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES     131    131       Phosphoserine; alternate.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES     178    178       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES     309    309       Phosphothreonine; by PDPK1.
FT                                {ECO:0000269|PubMed:12434148,
FT                                ECO:0000269|PubMed:15890450,
FT                                ECO:0000269|PubMed:20059950,
FT                                ECO:0000269|PubMed:9512493}.
FT   MOD_RES     447    447       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   MOD_RES     449    449       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES     451    451       Phosphothreonine.
FT                                {ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES     474    474       Phosphoserine.
FT                                {ECO:0000269|PubMed:15890450,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20059950}.
FT   MOD_RES     475    475       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P31749}.
FT   MOD_RES     478    478       Phosphoserine.
FT                                {ECO:0000269|PubMed:19690332}.
FT   CARBOHYD    128    128       O-linked (GlcNAc); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    131    131       O-linked (GlcNAc); alternate.
FT                                {ECO:0000250}.
FT   CARBOHYD    306    306       O-linked (GlcNAc). {ECO:0000250}.
FT   CARBOHYD    313    313       O-linked (GlcNAc). {ECO:0000250}.
FT   DISULFID     60     77       {ECO:0000250}.
FT   DISULFID    297    311       {ECO:0000269|PubMed:12517337}.
FT   VAR_SEQ     278    320       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056930.
FT   VARIANT      17     17       E -> K (in HIHGHH; exhibits plasma
FT                                membrane localization in serum-starved
FT                                cells and produced inappropriate tonic
FT                                nuclear exclusion of FOXO1 in
FT                                preadipocytes).
FT                                {ECO:0000269|PubMed:21979934}.
FT                                /FTId=VAR_067309.
FT   VARIANT     188    188       I -> V (in dbSNP:rs55859611).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040356.
FT   VARIANT     208    208       R -> K (in dbSNP:rs35817154).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040357.
FT   VARIANT     274    274       R -> H (in NIDDM; associated with typical
FT                                metabolic dyslipidemia with elevated
FT                                fastin triglyceride, high VLDL
FT                                triglyceride/cholesterol ratios, low HDL
FT                                cholesterol levels and high small dense
FT                                LDL levels; de novo lipogenesis and liver
FT                                fat are also significantly elevated in
FT                                this subject).
FT                                {ECO:0000269|PubMed:15166380}.
FT                                /FTId=VAR_067310.
FT   MUTAGEN     309    309       T->A: Impairs interaction with TTC3; when
FT                                associated with A-474.
FT                                {ECO:0000269|PubMed:15890450,
FT                                ECO:0000269|PubMed:20059950}.
FT   MUTAGEN     309    309       T->E: Constitutively active; when
FT                                associated with D-474.
FT                                {ECO:0000269|PubMed:15890450,
FT                                ECO:0000269|PubMed:20059950}.
FT   MUTAGEN     474    474       S->A: Impairs interaction with TTC3; when
FT                                associated with A-309.
FT                                {ECO:0000269|PubMed:15890450,
FT                                ECO:0000269|PubMed:20059950}.
FT   MUTAGEN     474    474       S->D: Constitutively active; when
FT                                associated with E-309.
FT                                {ECO:0000269|PubMed:15890450,
FT                                ECO:0000269|PubMed:20059950}.
FT   CONFLICT    478    481       SIRE -> FREEKDLLMSLFVSLILFSDFSSLKSHSFSSNF
FT                                ILLSFSSLKK (in Ref. 1; AAA36585).
FT                                {ECO:0000305}.
FT   STRAND        6     15       {ECO:0000244|PDB:1P6S}.
FT   STRAND       17     20       {ECO:0000244|PDB:1P6S}.
FT   STRAND       22     30       {ECO:0000244|PDB:1P6S}.
FT   TURN         31     33       {ECO:0000244|PDB:1P6S}.
FT   STRAND       34     40       {ECO:0000244|PDB:1P6S}.
FT   STRAND       45     47       {ECO:0000244|PDB:1P6S}.
FT   STRAND       52     56       {ECO:0000244|PDB:1P6S}.
FT   STRAND       58     60       {ECO:0000244|PDB:1P6S}.
FT   STRAND       62     65       {ECO:0000244|PDB:1P6S}.
FT   STRAND       67     75       {ECO:0000244|PDB:1P6S}.
FT   STRAND       86     92       {ECO:0000244|PDB:1P6S}.
FT   HELIX        93    110       {ECO:0000244|PDB:1P6S}.
FT   HELIX       149    151       {ECO:0000244|PDB:1O6L}.
FT   STRAND      152    160       {ECO:0000244|PDB:1O6L}.
FT   STRAND      162    171       {ECO:0000244|PDB:1O6L}.
FT   TURN        172    174       {ECO:0000244|PDB:1O6L}.
FT   STRAND      177    184       {ECO:0000244|PDB:1O6L}.
FT   HELIX       185    190       {ECO:0000244|PDB:1O6L}.
FT   HELIX       194    205       {ECO:0000244|PDB:1O6L}.
FT   STRAND      215    220       {ECO:0000244|PDB:1O6L}.
FT   STRAND      222    230       {ECO:0000244|PDB:1O6L}.
FT   HELIX       237    244       {ECO:0000244|PDB:1O6L}.
FT   HELIX       249    268       {ECO:0000244|PDB:1O6L}.
FT   STRAND      280    283       {ECO:0000244|PDB:1O6L}.
FT   STRAND      289    291       {ECO:0000244|PDB:1O6L}.
FT   STRAND      298    300       {ECO:0000244|PDB:2UW9}.
FT   STRAND      310    312       {ECO:0000244|PDB:2JDO}.
FT   HELIX       314    316       {ECO:0000244|PDB:1O6L}.
FT   HELIX       319    322       {ECO:0000244|PDB:1O6L}.
FT   STRAND      323    325       {ECO:0000244|PDB:1O6L}.
FT   HELIX       331    345       {ECO:0000244|PDB:1O6L}.
FT   STRAND      351    353       {ECO:0000244|PDB:1GZK}.
FT   HELIX       355    364       {ECO:0000244|PDB:1O6L}.
FT   STRAND      371    373       {ECO:0000244|PDB:1GZN}.
FT   HELIX       375    384       {ECO:0000244|PDB:1O6L}.
FT   TURN        389    391       {ECO:0000244|PDB:1O6L}.
FT   TURN        393    395       {ECO:0000244|PDB:2X39}.
FT   TURN        397    399       {ECO:0000244|PDB:1O6L}.
FT   HELIX       400    404       {ECO:0000244|PDB:1O6L}.
FT   HELIX       407    409       {ECO:0000244|PDB:1O6L}.
FT   HELIX       414    418       {ECO:0000244|PDB:1O6L}.
FT   STRAND      431    434       {ECO:0000244|PDB:2JDR}.
FT   STRAND      437    439       {ECO:0000244|PDB:1GZO}.
FT   HELIX       441    444       {ECO:0000244|PDB:1O6L}.
FT   STRAND      474    476       {ECO:0000244|PDB:3D0E}.
FT   TURN        477    479       {ECO:0000244|PDB:3D0E}.
SQ   SEQUENCE   481 AA;  55769 MW;  B18C87A7246BFB24 CRC64;
     MNEVSVIKEG WLHKRGEYIK TWRPRYFLLK SDGSFIGYKE RPEAPDQTLP PLNNFSVAEC
     QLMKTERPRP NTFVIRCLQW TTVIERTFHV DSPDEREEWM RAIQMVANSL KQRAPGEDPM
     DYKCGSPSDS STTEEMEVAV SKARAKVTMN DFDYLKLLGK GTFGKVILVR EKATGRYYAM
     KILRKEVIIA KDEVAHTVTE SRVLQNTRHP FLTALKYAFQ THDRLCFVME YANGGELFFH
     LSRERVFTEE RARFYGAEIV SALEYLHSRD VVYRDIKLEN LMLDKDGHIK ITDFGLCKEG
     ISDGATMKTF CGTPEYLAPE VLEDNDYGRA VDWWGLGVVM YEMMCGRLPF YNQDHERLFE
     LILMEEIRFP RTLSPEAKSL LAGLLKKDPK QRLGGGPSDA KEVMEHRFFL SINWQDVVQK
     KLLPPFKPQV TSEVDTRYFD DEFTAQSITI TPPDRYDSLG LLELDQRTHF PQFSYSASIR
     E
//
